MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1073/pnas.1515281112

Медицинская библиотека · Proceedings of the National Academy of Sciences of the United States of America · 2015

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Davare Monika A, Vellore Nadeem A, Wagner Jacob P, Eide Christopher A, Goodman James R, Drilon Alexander, Deininger Michael W, O'Hare Thomas, Druker Brian J

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод в очереди

Аннотация

Oncogenic ROS1 fusion proteins are molecular drivers in multiple malignancies, including a subset of non-small cell lung cancer (NSCLC). The phylogenetic proximity of the ROS1 and anaplastic lymphoma kinase (ALK) catalytic domains led to the clinical repurposing of the Food and Drug Administration (FDA)-approved ALK inhibitor crizotinib as a ROS1 inhibitor. Despite the antitumor activity of crizotinib observed in both ROS1- and ALK-rearranged NSCLC patients, resistance due to acquisition of ROS1 or ALK kinase domain mutations has been observed clinically, spurring the development of second-generation inhibitors. Here, we profile the sensitivity and selectivity of seven ROS1 and/or ALK inhibitors at various levels of clinical development. In contrast to crizotinib's dual ROS1/ALK activity, cabozantinib (XL-184) and its structural analog foretinib (XL-880) demonstrate a striking selectivity for ROS1 over ALK. Molecular dynamics simulation studies reveal structural features that distinguish the ROS1 and ALK kinase domains and contribute to differences in binding site and kinase selectivity of the inhibitors tested. Cell-based resistance profiling studies demonstrate that the ROS1-selective inhibitors retain efficacy against the recently reported CD74-ROS1(G2032R) mutant whereas the dual ROS1/ALK inhibitors are ineffective. Taken together, inhibitor profiling and stringent characterization of the structure-function differences between the ROS1 and ALK kinase domains will facilitate future rational drug design for ROS1- and ALK-driven NSCLC and other malignancies.

Для цитирования: Davare Monika A, Vellore Nadeem A, Wagner Jacob P, Eide Christopher A, Goodman James R, Drilon Alexander, Deininger Michael W, O'Hare Thomas, Druker Brian J. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.. Proceedings of the National Academy of Sciences of the United States of America. 2015. DOI: 10.1073/pnas.1515281112.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.